218 related articles for article (PubMed ID: 22889757)
1. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
[TBL] [Abstract][Full Text] [Related]
2. HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.
Amria S; Hajiaghamohseni LM; Harbeson C; Zhao D; Goldstein O; Blum JS; Haque A
Eur J Immunol; 2008 Jul; 38(7):1961-70. PubMed ID: 18506881
[TBL] [Abstract][Full Text] [Related]
3. Antigen-presenting cells and the selection of immunodominant epitopes.
Blum JS; Ma C; Kovats S
Crit Rev Immunol; 1997; 17(5-6):411-7. PubMed ID: 9419428
[TBL] [Abstract][Full Text] [Related]
4. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
5. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
6. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
7. Functional HLA-DM on the surface of B cells and immature dendritic cells.
Arndt SO; Vogt AB; Markovic-Plese S; Martin R; Moldenhauer G; Wölpl A; Sun Y; Schadendorf D; Hämmerling GJ; Kropshofer H
EMBO J; 2000 Mar; 19(6):1241-51. PubMed ID: 10716924
[TBL] [Abstract][Full Text] [Related]
8. HLA-DM and the MHC class II antigen presentation pathway.
Jensen PE; Weber DA; Thayer WP; Chen X; Dao CT
Immunol Res; 1999; 20(3):195-205. PubMed ID: 10741860
[TBL] [Abstract][Full Text] [Related]
9. Presentation of abundant endogenous class II DR-restricted antigens by DM-negative B cell lines.
Kovats S; Whiteley PE; Concannon P; Rudensky AY; Blum JS
Eur J Immunol; 1997 Apr; 27(4):1014-21. PubMed ID: 9130658
[TBL] [Abstract][Full Text] [Related]
10. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
Goldstein OG; Hajiaghamohseni LM; Amria S; Sundaram K; Reddy SV; Haque A
Cancer Immunol Immunother; 2008 Oct; 57(10):1461-70. PubMed ID: 18343923
[TBL] [Abstract][Full Text] [Related]
11. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing.
Bellemare-Pelletier A; Tremblay J; Beaulieu S; Boulassel MR; Routy JP; Massie B; Lapointe R; Thibodeau J
J Leukoc Biol; 2005 Jul; 78(1):95-105. PubMed ID: 15817706
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus.
Johnson DC; Hegde NR
Curr Top Microbiol Immunol; 2002; 269():101-15. PubMed ID: 12224504
[TBL] [Abstract][Full Text] [Related]
13. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
14. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
Stebbins CC; Loss GE; Elias CG; Chervonsky A; Sant AJ
J Exp Med; 1995 Jan; 181(1):223-34. PubMed ID: 7807005
[TBL] [Abstract][Full Text] [Related]
15. Antigen processing: HLA-DO--a hitchhiking inhibitor of HLA-DM.
Jensen PE
Curr Biol; 1998 Feb; 8(4):R128-31. PubMed ID: 9501976
[TBL] [Abstract][Full Text] [Related]
16. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes.
Kropshofer H; Spindeldreher S; Röhn TA; Platania N; Grygar C; Daniel N; Wölpl A; Langen H; Horejsi V; Vogt AB
Nat Immunol; 2002 Jan; 3(1):61-8. PubMed ID: 11743588
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
Hegde NR; Tomazin RA; Wisner TW; Dunn C; Boname JM; Lewinsohn DM; Johnson DC
J Virol; 2002 Nov; 76(21):10929-41. PubMed ID: 12368336
[TBL] [Abstract][Full Text] [Related]
18. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
19. Distinct editing functions of natural HLA-DM allotypes impact antigen presentation and CD4
Álvaro-Benito M; Morrison E; Ebner F; Abualrous ET; Urbicht M; Wieczorek M; Freund C
Cell Mol Immunol; 2020 Feb; 17(2):133-142. PubMed ID: 30467419
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells.
Tomazin R; Boname J; Hegde NR; Lewinsohn DM; Altschuler Y; Jones TR; Cresswell P; Nelson JA; Riddell SR; Johnson DC
Nat Med; 1999 Sep; 5(9):1039-43. PubMed ID: 10470081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
